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It has been estimated that approximately 1% of the general population are ataxia telangiectasia (AT) mutated (ATM) heterozygotes.
The ATM protein plays a central role in DNA-damage response pathways; however, the functional consequences of the presence of
either heterozygous truncating or missense mutations on ATM expression and the ionising radiation (IR)-induced cellular phenotype
remain to be fully determined. To investigate this relationship, the ATM mRNA and protein levels and several cellular end points were
characterised in 14 AT heterozygote (AT het) lymphoblastoid cell lines, compared to normal and AT homozygote lines. The AT het
cell lines displayed a wide range of IR-induced responses: despite lower average levels of ATM mRNA and protein expression
compared to normal cells, 13 out of 14 were capable of phosphorylating the ATM substrates p53-ser15 and Chk2, leading to a
normal cell cycle progression after irradiation. However, cell survival was lower than in the normal cell lines. The presence of a
missense compared to a truncating mutation was associated with lower cell survival after exposure to 2Gy irradiation (P¼0.005),
and a higher level of ATM mRNA expression (P¼0.047). Our results underline the difficulty in establishing a reliable test for
determining ATM heterozygosity.
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Ataxia telangiectasia (AT) is a rare autosomal recessive multi-
systemic disorder with neurological, cutaneous and immunological
abnormalities. This disease is associated with an elevated risk of
malignancy, primarily leukaemias and lymphomas, and a high
radiosensitivity. The gene defective in this syndrome, ATM (AT
mutated), encodes a nuclear 350kDa phosphoprotein containing a
carboxy terminus phosphatidylinositol 30-kinase (PI-30 kinase)
catalytic domain shared by members of a superfamily of large
eukaryotic proteins involved in intracellular signalling, DNA
damage-induced cell cycle checkpoints, DNA repair and recombi-
nation (reviewed in Khanna et al, 2001). After exposure of cells to
ionising radiation (IR) or radiomimetic drugs, ATM’s kinase
activity increases several-fold, although the protein level remains
unchanged. In the DNA-damage response pathway, ATM acts
upstream of p53 to induce cell cycle arrest at the G1/S and G2/M
boundaries and a slowing of the S phase (Hoekstra, 1997). At least
part of this activation mechanism involves phosphorylation of p53
on serine-15 that may contribute to the increased half-life of p53
by facilitating its dissociation from MDM2, a protein that
promotes p53 proteolysis (Nakagawa et al, 1999). Signalling by
ATM also involves interactions with and phosphorylation of the
mitotic checkpoints Chk1 and Chk2 (Chen et al, 1999; Matsuoka
et al, 2000). Cells from AT homozygotes show a reduced induction
of p53 levels after exposure to IR compared with normal cells, and
an altered cell cycle progression with an accumulation in the G2
phase of the cell cycle postirradiation and radioresistant DNA
synthesis occurring. Loss of ATM function is also associated with
increased genomic instability that contributes to the increased
incidence of cancers seen in this syndrome (reviewed in Shiloh,
2003).
A wide spectrum of ATM mutations is found in AT patients.
Most are compound heterozygous and, in some populations, there
is a strong founder effect (Concannon and Gatti, 1997). About 70%
of the ATM mutations identified in AT patients are truncating
mutations (ATM
trunc), with about 30% being missense mutations
and small in-frame deletions/insertions (ATM
mis) (Gilad et al,
1996; Stankovic et al, 1998). In many such studies, only the protein
truncation test has been used to identify mutations, inevitably
creating a bias in the mutations reported; thus, the percentage of
truncating mutations could be an overestimate. Truncating
mutations act effectively as null mutations, as they result in an
unstable protein that is present in very small amounts within a cell.
In contrast, missense mutations lead to the expression of a more
stable albeit mutant form of the ATM protein, as has been
described for the few homozygotes carriers of missense mutations
that have been studied (Angele ` et al (2003) and references therein).
Heterozygous carriers of the ATM gene (AT hets) have been
estimated to comprise 0.36–1% of the general population. These
individuals show none of the severe clinical symptoms seen in AT
patients, but have a higher risk of developing several forms of
cancer, particularly breast cancer (BC) in women and an earlier
age at death from ischaemic heart disease than noncarriers (Su and
Swift, 2000). On the basis of the increased risk of BC and the
heterozygote frequency in the general population, it has been
estimated that about 5% of BC patients could be ATM mutation
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scarriers. Since the ATM gene was cloned, many efforts have been
made to evaluate the public health implications of this observation
by screening cohorts of BC patients for ATM mutations. The first
published studies produced conflicting results, and did not reveal
the magnitude of involvement of the ATM gene in sporadic BC that
would have been expected from the increased risk found in the AT
family studies and the frequency of AT heterozygotes in the
population. To resolve this paradox, it has been hypothesised that
there are two populations of AT carriers, one group with a
truncating allele coupled with a normal allele (AT hets
trunc) and a
second group with a missense mutation coupled with a normal
allele (AT hets
mis), and that the latter group might be more prone
to cancer development (McConville et al, 1996; Gatti et al, 1999;
Meyn, 1999). Indeed, there is some experimental evidence that
carrying an ATM missense mutation could lead to a dominant-
negative phenotype in human cell lines (Chenevix-Trench et al,
2002; Scott et al, 2002), with competition between the mutant and
the wild-type forms of the ATM protein.
The establishment of ATM heterozygosity is essential for the
estimation of cancer risks and genetic counselling. For instance,
intermediate sensitivity to IR has been documented in cell lines
from AT heterozygotes using the measurement of cell survival or
chromosome damage induction as end points (Chen et al, 1978;
Rosin and Ochs, 1986; Shiloh et al, 1986; Scott et al, 1996; Tchirkov
et al, 1997; Neubauer et al, 2002). However, many such studies
have characterised only cell lines carrying truncating mutations,
and some variability in the cellular responses has been noted
between different cell lines (Nagasawa et al, 1985; Shiloh et al,
1989; Pandita and Hittelman, 1994; Djuzenova et al, 1999). In order
to establish which methods, other than mutation screening, might
provide reliable end points for determining ATM heterozygosity,
we have compared the cellular phenotype before and after
exposure to IR of AT heterozygote cell lines with that seen in
cell lines carrying a wild type or homozygous mutated ATM gene.
To assess whether ATM
mis and ATM
trunc mutations have distinct
effects on ATM protein function, this comparison was made using
three heterozygote cell lines carrying missense and 11 carrying
truncating mutations. The end points examined were the
constitutive levels of ATM mRNA and protein expression and
the cell cycle delay in G2 phase, the phosphorylation of Chk2 and
serine 15 of p53 and the cell survival after exposure to IR.
MATERIALS AND METHODS
Cell lines
Lymphoblastoid cell lines (LCLs), established by Epstein–Barr
virus infection of ficoll-purified lymphocytes, were used through-
out this study. The seven normal LCLs (IARC 2139, 2145, 2093,
1326, 1663, 1104 and 2209) and the six AT LCLs (IARC AT3, AT6,
AT8, AT11, AT13 and AT14) were obtained from Dr Gilbert Lenoir
(Institute Gustave Roussy, Villejuif, France). All the AT LCLs
carried ATM mutations resulting in a truncated ATM protein
(Gilad et al, 1996; Hacia et al, 1998; Ange `le et al, 2003). It should be
noted that the AT lines IARC AT13 and AT14 were established
from sibling pairs and carry the same homozygous truncating
mutation. The ATM gene status of the normal cell lines has been
previously determined using the restriction endonuclease finger-
printing technique, and all lines carried a wild-type ATM gene
(unpublished data). The 14 AT heterozygote LCLs used in this
study were all established from the parents of AT children. The
ATM gene status in these lines was determined using the FAMA
technique (Verpy et al, 1994). All carried either a truncating or a
missense mutation (Table 1). The cell line 1–21953 was found to
be carrying a missense sequence alteration G544C and a truncating
mutation trp2368stop. This missense alteration has not been
previously described as a polymorphism in the ATM mutation
database (http://www.benaroyaresearch.org/bri_investigators/
atm.htm). It has been reported as a rare variant (allele frequency
0.015) by Izatt et al (1999), and found in the heterozygous state in
four out of 65 individuals of North African origin (Hall,
unpublished data), and thus was considered as an ATM
polymorphism in this present study.
Table 1 Characteristics of AT heterozygote cell lines
Cell survival Cell ATM ATM
Cell line
Mutation type
Position (amino-acid change)
Mutation
localisation 1Gy 2Gy 4Gy
cycle
G2/G1
protein
level
mRNA
level p53-ser15 Chk2
1–17178 Truncating – 381delA (ter aa1280) Exon 7 AT AT AT N Int AT N N
1–19320 Truncating – 3403del174 (NP-58aa
a) Exon 26 Int Int AT N Int Int N N
1–21954 Truncating – 3576del170 (ter aa1196) Exon 27 Int Int AT N N Int N N
1–17179 Truncating – 3711del5 (ter aa1243) Exon 27 N N AT N N AT N N
1–17814 Truncating – 4661insA (ter aa1560) Exon 33 AT Int AT N N N N N
10–572 Truncating – C6004T (gln202stop) Exon 42 N Int AT Int Int Int Int N
1–17180 Truncating – C7327T (arg2443stop) Exon 52 AT Int Int N Int Int N N
1–17815 Truncating – 7789del139 (ter aa2599) Exon 55 AT AT AT N Int Int Int N
1–21953 Truncating – G7913A (trp2638stop) Exon 55 AT AT AT N N Int N N
1–17052 Truncating – 8030delA (ter aa2681) Exon 57 AT AT AT N N AT N N
10–573 Truncating – C8140T (gln2714stop) Exon 57 N N Int N Int AT N N
All Truncating Int Int AT N Int Int N N
1–15308 Missense – TG7875GG (asp-ala2652glu-pro) Exon 55 AT AT AT N N N Int N
1–17053 Missense – T8489G (val2830gly) Exon 60 AT AT AT N Int N Int N
1–25065 Missense – T8479G (phe2827ile) Exon 60 Int AT AT N N Int N N
All Missense AT AT AT N N Int N N
All Int Int AT N Int Int N N
aNP – native protein lacking 58 amino acids encoded by exon 26. ter – protein termination. ‘N’ and ‘AT’ mean that the results obtained for the AT het line were not statistically
significantly different from that obtained for the normal or AT LCLs, respectively. ‘Int’ means that this result was significantly different from those of both the normal and AT LCLs.
ATM mutation status and response to ionising radiation
M Fernet et al
867
British Journal of Cancer (2004) 90(4), 866–873 & 2004 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sLCLs were routinely maintained at 371C, in a humidified
incubator with 5% CO2, in exponential growth by dilution twice a
week to 5 10
5cellsml
 1 in RPMI1640 medium (Gibco, Invitrogen
Corporation, Cergy-Pontoise, France) supplemented with 10%
heat-inactivated foetal calf serum (Integro b.v, Zaandan, Holland)
and penicillin and streptomycin (100mgml
 1, Gibco).
ATM protein expression
A whole-cell protein extract was prepared, as previously described,
from lymphoblastoid cells plated at 5 10
5 cells, the day before
extraction (Jongmans et al, 1998). 50mg of this protein extract was
separated on a 6% biphasic SDS–polyacrylamide gel, transferred
overnight at 30V onto a PVDF membrane (Roche Diagnostics)
using the Bio-Rad Trans-Blot Cell (Bio-Rad, Marnes la Coquette,
France) and immunoblotted using an ATM antibody (AHP392,
Serotec, 1/1000 dilution) and a ku80 antibody (AHP317, Serotec, 1/
40000 dilution). After a 2h incubation with the primary
antibodies, the membranes were probed with peroxidase-con-
jugated goat anti-rabbit IgG (DAKO, Denmark) and developed
using a chemiluminescence procedure (Amersham, Piscataway, NJ,
USA). The expression levels of each protein were determined by
densitometry, after correction for protein loading using Ku80 as an
internal standard (ATM/Ku80 ratio). Measurements were made at
least twice using two independently prepared protein extracts.
Analysis of ATM mRNA levels
RNA isolation and cDNA synthesis Total RNA was isolated from
0.5 10
7 cells plated at 5 10
5 cellsml
 1 the day before extraction,
using the RNazol extraction method (Invitrogen). Reverse
transcription was carried out on 5mg of total RNA in a 20-ml
reaction volume containing 1  first-strand buffer, 200U of
Superscript II RNase H-reverse transcriptase, 40U of RNase
inhibitor (Promega, Charbonnieres, France), 10mM DTT (Invitro-
gen), 125mM of each dNTP and 0.5mg of oligo(dT)15 (Promega) for
1h at 421C. The resulting cDNA were used for real-time
amplification reactions.
Quantitative real-time PCR The mRNA levels of the ATM gene
were measured following generation of the corresponding cDNA
by real-time PCR based on TaqMan chemistry, and quantitated
using an ABI PRISM 7900 HT sequence detector system (Applied
Biosystems, Les Ulis, France). The cDNA levels of an internal
control gene, the Actin gene, were measured and used to normalise
the ATM cDNA levels. Oligonucleotide primers and Taqman
probes for ATM were designed from the Genbank databases using
Primer Express (Applied Biosystems). The probes for human ATM
and Actin used in the PCR reactions were located in two adjacent
exons of each gene to avoid amplification of any genomic DNA
contaminating the cDNA.
The ATM forward primer was 50-GAGCAGAGTCTTGCCCT-
GAGTATT-30 and the reverse primer was 50-TTGCCACAAACCCT-
CAGACA-30.
The Actin forward primer was 50-CTGGCACCCAGCACAATG-30
and the reverse primer was 50-GCCGATCCACACGGAGTACT-30.
The Taqman probe for ATM was 50-CTGTGCAGCGAACAATCC-
CAGCCT-30 and had a fluorescent reporter dye (FAM) covalently
linked to its 50 end. The Taqman probe for Actin was 50-
TCAAGATCATTGCTCCTCCTGAGCGC-30 and had a fluorescent
reporter dye (TET) covalently linked to its 50. The nonfluorescent
quencher dye BHQ1 was linked to the 30 end of each probe. The
reaction mixture contained 0.2ml of cDNA template, 50nM of Actin
primers, 2mM of ATM primers, 100nM of TaqMan ATM probe,
200nM of TaqMan Actin probe and 1  TaqMan universal master
mix (Applied Biosystems). Amplification and detection of specific
products was carried out in an ABI PRISM 7900 HT sequence
detection system (Applied Biosystems) using an amplification
protocol consisting of an initial denaturing and enzyme activation
at 951C for 10min, followed by 35 cycles at 941C for 15s and 621C
for 1min. For each sample, three independent RNA extractions
have been analysed, with each corresponding cDNA analysed six
times on the same plate.
The threshold cycle (Ct), defined as the cycle where the
amplification of the PCR product enters the exponential phase,
was determined for each gene by plotting the fluorescence level vs
the cycle number on a logarithmic scale. The relative expression
level of the ATM gene in the different cell lines was then estimated
using a semiquantitative method, by calculating the DCt value,
defined as the difference in the Ct value for the target (ATM) and
the reference gene (Actin). The results are expressed as the ratio
100/DCt for ease of interpretation.
Cell survival
The radiation survival of the LCLs was measured by their relative
growth at 72h postirradiation (Gilad et al, 1996). The cells were
seeded at 2 10
5cellsml
 1 the day before irradiation and cell
survival was assessed 3 days after exposure to 0, 1, 2 and 4Gy from
a
137Cs source, at a dose rate of about 5Gymin
 1, by counting the
number of living cells using trypan blue exclusion. The number of
viable cells in the nonirradiated culture 72h postirradiation was
considered as 100% cell survival. Experiments were performed at
least twice on each cell line with at least one normal and one AT
LCL being analysed in parallel.
p53 and Chk2 phosphorylation
Measurements of p53-ser15 and Chk2 phosphorylation were made
in total protein extracts prepared from control or irradiated (5Gy)
LCLs (10
7 cells plated at 5 10
5 cellsml
 1 the day before). Briefly,
cells were collected from untreated or treated cells 2 and 4h after
treatment, washed twice in PBS and lysed in TGN buffer (50mM
Tris-HCl pH 7.5, 150mM NaCl, 1% Tween 20, 0.2% Nonidet-P40,
0.2mgml
 1 pefabloc
R (Boehringer, Roche Diagnostics, Grenoble,
France), 1mM sodium fluoride, 1mM sodium orthovanadate,
10mgml
 1 aprotinin, 2mgml
 1 pepstatin A and 5mgml
 1 leupep-
tin for 30min on ice. The supernatant was collected after
centrifugation for 15min at 15000r.p.m. (41C), and its protein
concentration determined using the BIO-RAD protein assay. 50mg
of this protein extract was separated on a 10% biphasic SDS–
polyacrylamide gel and transferred overnight onto a PVDF
membrane, as described above. The p53-ser15 phosphorylation
was measured using a specific p53-phosphoserine 15 antibody
(#9284, Cell Signaling Technology, 1/1000 dilution), and the Chk2
phosphorylation was detected by the mobility shift of the protein
using a specific Chk2 antibody (477, Abcam, 1/1500 dilution). The
expression levels of each protein were determined by densitome-
try, after correction for protein loading using Ku80 as an internal
standard, as described above. Measurements were made at least
twice from a minimum of two independently prepared protein
extracts.
Cell cycle analysis
7.5 10
6 cells (plated at 5 10
5 cellsml
 1) were plated into two
flasks and left to grow overnight. One flask was subsequently used
as a control and the second treated with 5Gy of IR. At 0, 24 and
48h postirradiation, an aliquot of the control and treated cells were
collected, washed in PBS and treated with propidium iodide using
the CycleTestt Plus Kit (Becton Dickinson, Pont-de-Claix,
France), according to the manufacturer’s instructions. The DNA
content was analysed by flow cytometry (FACSCalibur, Becton
Dickinson), using the CellQuest software; 10000 events were
analysed for each sample. The percentage of cells in each phase of
the cell cycle was determined using the ModFit programme.
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The cell cycle defect was investigated by calculation of the ratio (%
of cells in G2 phase)/(% of cells in G1 phase), representative of the
delay in G2 occurring after exposure to IR (Lavin et al, 1992).
Statistical methods
The differences in the basal levels of ATM mRNA and ATM
protein, cell survival and the induction of the phosphorylation of
p53 in response to DNA damage between the LCLs established
from the normal donors, the AT homozygote patients and the AT
heterozygotes have been tested by the analysis of the variance
(ANOVA). For the intergroup comparison, significant heteroge-
neity in the variance was assessed by the Bartlett test, and, if
necessary, transformations of the variables were applied: arc sine
of the square root for cell survival after 1 and 2Gy, and logarithm
for ATM protein level and p53 phosphorylation. For some
comparisons, it was impossible to stabilise the variance, so
a Mann–Whitney U-test was used (ATM mRNA level, G2/G1
ratio and cell survival after 4Gy). All the statistical computations
were performed using the STATISTICA software (version 5.97,
Statsoft).
RESULTS
ATM protein and mRNA levels in normal, AT heterozygote
and AT cells
The mean values of ATM protein levels for the 14 AT het cell lines,
three carrying missense mutations and 11 truncating mutations, in
comparison to the three normal cell lines analysed, are presented
in Figure 1. The AT cell line (AT11) carrying two heterozygous
truncating mutations, with a very low level of ATM protein that is
a characteristic of cells from many AT patients, is included as a
negative control. On an individual basis, half of the AT het cell
lines examined showed a 20–30% lower expression of ATM
protein (Table 1) compared to the normal cell lines. As a group,
the AT het LCLs expressed significantly less ATM protein than the
normal cell lines (P¼0.002), but more than AT11 (Po0.001).
There were no statistical differences in the protein levels between
the three AT hets
mis LCLs studied, compared to the 11 AT hets
trunc
LCLs (P¼0.110) studied. However, the AT hets
trunc as a group had
a statistically lower ATM protein level than the normal cell lines
(Po0.001), while the group of AT hets
mis were indistinguishable
from the normal LCLs in terms of ATM protein expression
(P¼0.102).
The mean values of a ratio proportional to the DCt values,
representative of the ATM mRNA level, for the six normal, three
AT and all the AT het cell lines are presented in Figure 2. As a
group, the AT het cell lines exhibited an intermediate mRNA level
lower than that of the normal (Po0.001) and higher than that seen
in the AT cell lines (Po0.001), with some variation between the
different lines being seen. The AT hets
mis as a group had lower
ATM mRNA levels than the normal cell lines (P¼0.002), and
higher levels than the AT (Po0.001) and AT hets
trunc (P¼0.047)
cell lines. The mRNA levels in the AT hets
trunc cell lines were also
intermediate between the normal (Po0.001) and the AT lines
(Po0.001).
Cell survival
The relative cell survival of the cell lines studied after exposure to
1, 2 and 4Gy is shown in Figure 3. Statistical analysis of the results
was done for each dose separately. The cell survival of the six
normal and the six AT cell lines was of the same order, as
previously found, under identical experimental conditions (Ange `le
et al, 2003). Considerable variation was seen between the different
AT het cell lines but, as a group, they had a cell survival level which
was intermediate and distinguishable between that seen in the
normal (Po0.001) and AT (Po0.001) LCLs after exposure to 1 and
2Gy. It was, however, indistinguishable from that of the AT LCLs
after exposure to 4Gy (P¼0.604).
Differences were noted in the cell survival profile between the
two groups of AT het LCLs studied. The group carrying a missense
mutation had a lower average cell survival, which was distinguish-
able from that of the LCLs carrying truncating mutations after
exposure to 2Gy (P¼0.005), but not after exposure to 1Gy
(P¼0.271). The survival of the AT hets
mis was indistinguishable
from that of the AT LCLS after exposure to 1 and 2Gy (P¼0.072
and 0.803, respectively), while the AT hets
trunc group showed a
higher survival at both doses (Po0.001 for 1 and 2Gy). After
exposure to 4Gy, the two groups of AT hets were as radiosensitive
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Figure 1 ATM protein levels in the normal (IARC 2093, 2145, 2139),
AT (AT11), AT hets
trunc and AT hets
mis LCLs examined. The level of ATM
was calculated from the densitometric analysis of Western blot films, after
correction for protein loading using Ku80 as a marker. The average
intensity7s.d. was determined for each group of cell types, with at least
two measurements made for each line (n¼number of lines in each group).
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Figure 2 ATM-mRNA level in the six normal, three AT (AT6, AT11,
AT14), 11 AT hets
trunc and three AT hets
mis LCLs. The mRNA level,
expressed as the ratio 100/DCT, was obtained by TaqMan analysis and
correction for RNA content using b-actin. Data points represent the mean
value from at least three experiments for each of the cell lines studied
(n¼number of lines in each group), except for AT6 and AT14, which were
assayed twice.
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trunc and
AT hets
mis, respectively).
Phosphorylation of Chk2 and p53-serine 15
The phosphorylation of the two ATM-target proteins Chk2 and
p53-ser15 was studied 2 and 4h after a 5Gy irradiation by Western
blot analysis (Figure 4). The AT het cell lines were compared with
two normal and an AT LCLs, representative of each cell type. As
expected, the AT11 LCL exhibited a reduced phosphorylation of
p53-ser15 and no shift in the position of Chk2, 2 or 4h after
exposure to IR, while the normal cell lines showed a maximum
p53-ser15 phosphorylation 2h after treatment and a clear shift in
the mobility of Chk2. The average levels of the p53-ser15 induction
for the four cell types are shown in Figure 5. No differences were
noted between the group of AT hets
mis or AT hets
trunc and the
normal LCLs (P¼0.355 and 0.279, respectively). However, on an
individual cell line basis of the 14 AT hets LCLs studied, a delayed
and reduced p53-ser15 phosphorylation was noted in four lines
(10-572, 1-17815, 1-15308 and 1-17053). All the AT het cell lines
showed a Chk2 bandshift after exposure to IR, as seen in the
normal cell lines.
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Figure 3 Radiation cell survival curves. The viable cells were counted by
trypan blue exclusion 3 days after exposure to gamma radiation. Mean
values7s.d. for each group of cell lines were established based on the
results from at least two independent experiments on each line.
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Figure 4 Radiation-induced Chk2 and p53-ser15 phosphorylation. Protein extracts were prepared from the normal (IARC 2145), AT (AT11) and AT
heterozygote (10–573, 1–15308, 1–17815, 1–17053, 10–572 and 1–25065) LCLs 2 and 4h after exposure to 5Gy, and from untreated cells. Ku80
immunodetection was performed on each gel to correct for variations in protein loading. Phosphorylation of Chk2 was assessed by the mobility shift of the
protein band, while the intensity of the p53-ser15 bands was analysed by densitometry.
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Figure 5 Quantification of the p53-ser15 phosphorylation, presented as
the p53-ser15/ku80 ratio to correct for variation in protein loading, 2 and
4h after exposure to 5Gy IR. The average ratio7s.d. was calculated for
each group of cell lines, based on at least two independent experiments for
each line (n¼number of lines).
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The radiation-induced arrest in the G2 phase of the cell cycle was
assessed by calculating the ratio between the percentage of cells in
G2 and the percentage of cells in G1, 24 and 48h after irradiation
(Figure 6). All the statistical analyses were made by taking into
account the results at 24 and 48h after irradiation. As previously
noted, the six AT cell lines showed a greater cell cycle delay in G2,
reflected in a higher G2/G1 ratio, compared to the six normal cell
lines (Po0.001) (Ange `le et al, 2003). As a group, the 14 AT het cell
lines presented a G2/G1 ratio similar to that of the normal cell lines
(P¼0.382), with no differences being noted depending on the type
of mutation being carried (P¼0.894 and 0.494 for AT hets
trunc and
AT hets
mis, respectively). We, however, noted that two AT het
LCLs, both carrying a truncating ATM mutation, showed a higher
G2/G1 ratio than the normal LCLs (AT het cell line 10-572,
P¼0.025 and 1-17815, P¼0.056).
DISCUSSION
It has been postulated and supported by limited experimental
evidence that the presence of ATM missense mutations, in contrast
to ATM truncating mutations, may result in a different cellular
phenotype after exposure to IR and alter the risk of developing
cancers in heterozygote carriers (Stankovic et al, 1998; Gatti et al,
1999; Chenevix-Trench et al, 2002; Scott et al, 2002). We have
investigated the constitutive levels of expression of the ATM gene
and the in vitro cellular phenotype after exposure to IR in 14
heterozygote cell lines carrying different mutations located
throughout the ATM gene, to assess whether mutation-type
specific differences could be detected and whether such end points
could provide a reliable assay for the identification of ATM
carriers. A wide range of responses was noted, extending from that
seen in normal cell lines to the extreme reactions seen in
homozygote carriers of ATM mutations, with the profile of
responses of each line varying in its severity depending on the
end point being measured and the treatment dose (Table 1).
As a group, the AT heterozygotes had a reduced level of ATM
mRNA expression, which was reflected in a lower average
constitutive level of protein expression, compared to the normal
LCLs studied. The assessment of the gene expression phenotype
has been proposed as a possible means of identifying ATM
heterozygotes (Watts et al, 2002), and these results would lend
support to this proposal. However, it should be noted that some
variation between the different LCLs was noted and no direct
relationship between the ATM protein and mRNA levels was seen
in all cell lines (Jongmans et al, 1997; Becker-Catania et al, 2000;
Sun et al, 2002). In this study, the three AT heterozygote cell lines
carrying a missense mutation had higher levels of mRNA levels, as
measured by a semiquantitative PCR-based technique compared to
the lines carrying truncating mutations, reflecting the observations
in ATM homozygote lines. However, differences in ATM protein
levels between the two groups of AT hets was not so clearcut, as
has been previously reported (Shigeta et al, 1999; Becker-Catania
et al, 2000; Delia et al, 2000). It should be noted that, under the
experimental conditions used, no truncated forms of the ATM
protein were detected in any of the heterozygote lines examined. It
cannot be excluded that differences in expression may also exist
between the two ATM alleles, as has been found to be the case in
XP-C heterozygotes where the expression of the normal allele
predominated (Chavanne et al, 2000).
Enhanced cell killing in response to treatment with IR is one
characteristic of all ATM homozygote cells, but the level of this
radiosensitivity in ATM heterozygote cells appears more variable.
Many authors have reported a level of cell survival intermediate
between that seen in normal and ATM homozygote cells, but, in
other studies, some overlap or no statistically significant
differences between normal and AT het cell types have been
detected (Chen et al, 1978; Kinsella et al, 1982; Nagasawa et al,
1985; Weeks et al, 1991; West et al, 1995; Shigeta et al, 1999; Sun
et al, 2002). Many of these studies have used a fibroblast-cloning
assay, which requires the trypsinising and replating of treated cells,
which may lead to additional cell death, particularly in radiation-
sensitive cell types. Using a cell proliferation assay, which avoids
the manipulation of the treated cells, our results indicated a greater
radiosensitivity for the AT heterozygote cells as a group, compared
with the normal cells. Some overlap between the results obtained
from the AT heterozygote and homozygote cells lines was noted, in
particular after exposure to 4Gy, suggesting that such high doses
are not the ideal experimental conditions to distinguish these two
cell types. When the distinction between the carriers of missense or
truncating mutations was made, we noted that the cell lines
carrying missense mutations were more radiosensitive than those
carrying truncating mutations after treatment. This observation
was based on the overlap of their survival with the AT cell lines at
lower doses, which was not seen for the AT het
trunc lines, and the
fact that the two groups could be distinguished after exposure to
2Gy. These findings suggest that the ATM protein containing a
missense mutation could act in a dominant-negative manner
influencing cell survival.
To evaluate the kinase activity of the ATM protein in the
heterozygote cells, the in vivo phosphorylation of the p53-ser15
and Chk2 was assessed after exposure to IR. The AT cell line
studied exhibited an approximately five-fold reduced p53-ser15
phosphorylation compared to the two normal cell lines under the
experimental conditions used. This p53-ser15 phosphorylation is
probably due to the kinase activity of ATR (ATM-related), which is
also able to carry out this specific p53 phosphorylation (Matsuoka
et al, 2000). However, no Chk2 phoshorylation, as assessed by the
alteration of its mobility on the SDS–PAGE gels, was noted in this
homozygote line. In contrast, under these same experimental
conditions, Chk2 phosphorylation was detected in all the 14 AT
heterozygote cell lines, and 10 of the 14 cell lines showed a normal
level of p53-ser15 phosphorylation. A possible explanation of this
result is that a second kinase activity capable of carrying out these
reactions is present in these heterozygote lines at a higher level
than seen in normal cell lines, such as increased levels of ATR. It
should be noted that these two end points were assessed on the
same Western blots, so that these apparently substrate-specific
differences could not be explained by variability between protein
extracts, but reflect the in vivo pattern of phosphorylation that had
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Figure 6 Cell cycle delay in G2 phase. This delay was estimated in six
normal, six AT and the 14 AT het cell lines, by calculation of the G2/G1
ratio, 24 and 48h after exposure to 5Gy. Data points represent the
average value for each cell line, based on at least two independent
experiments.
ATM mutation status and response to ionising radiation
M Fernet et al
871
British Journal of Cancer (2004) 90(4), 866–873 & 2004 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
soccurred following exposure to IR. No mutation-type (truncating
vs missense) specific differences in the capacity to phos-
phorylate these ATM-target proteins were noted. Some variation
between ATM kinase activity has been reported in the
limited number of heterozygote lines previously studied (Delia
et al, 2000; Scott et al, 2002), suggesting that these end points are
not suitable for evaluating the presence of ATM heterozygosity
with certitude.
Alterations in the activation of p53, Chk2 and other proteins
lead to disturbances in cell cycle progression after irradiation.
Under such conditions, most AT cell lines fail to delay at the G1/S
and G2/M checkpoints, progressing through the cell cycle to
accumulate and die in G2/M. Thus, the G2/G1 ratio can be used to
estimate the accumulation of cells in G2/M after exposure to IR.
We found that the AT het cell lines as a group exhibited a delay in
G2 similar to that seen in the normal cell lines after such treatment.
An intermediate G2 delay has been reported previously in some AT
het cell lines between that observed in normal and AT cell lines,
but overlaps in the response between these three cell types have
also been reported (Lavin et al, 1992; Chen et al, 1994; Naeim et al,
1994). One explanation for these differences in the cell cycle profile
could be the radiation treatment dose used. In this present study,
the cell cycle progression was examined after an exposure to 5Gy,
while other studies have used lower treatment doses (2 or 3Gy). It
can be reasoned that, even if the pathways controlling the cell cycle
progression are not fully operational in AT heterozygote cells, after
exposure to higher doses of IR with greater levels of DNA damage
being formed, the activation of cell cycle regulation could occur,
perhaps through the intervention of other DNA damage-activated
kinases, leading to an apparently normal response. The lack of a
defect in cell cycle progression in the majority of the AT het LCLs
examined after exposure to IR is consistent with the normal
activation of p53 and Chk2 observed, two proteins strongly
involved in cell cycle checkpoint control. The one AT het line
which had a statistically lower G2/G1 ratio also showed a lower p53-
ser15 phosphorylation after treatment with IR, but a normal Chk2
response underlining the complex interplay of the proteins
controlling the cell cycle response to DNA damage. It would
appear in spite of a reduced ATM protein level in some ATM
carriers that this endogenous protein is sufficient to ensure the
functionality of the signalling pathways leading to cell cycle control
after exposure to IR, but not to ensure normal levels of cell
survival.
The variation between the different AT heterozygote lines
studied, especially in terms of ATM mRNA and protein levels and
cell survival, is large with some cell lines being indistinguishable
from normal cell lines, while others have a cellular phenotype
similar to that seen in AT homozygote lines. One explanation for
this interindividual variability might be the location of the
different ATM mutations within the gene, which may affect ATM
protein expression and/or its activity. Morgan et al (1997)
demonstrated that the expression of an ATM fragment encoding
the leucine zipper domain can act in a dominant-negative manner
influencing cell survival, but not p53 induction nor cell cycle
checkpoints, while expression of the PI-3 kinase domain is
sufficient to ensure ATM kinase activity (Morgan et al, 1997).
The mutations carried by the AT heterozygote cell lines included in
this present study were located throughout the ATM gene, and all
the truncating mutations were located upstream of the conserved
PI-3 kinase domain (codon 60/61). Thus, if a stable truncated
protein was expressed, it would contain the leucine zipper domain
and could potentially act in a dominant-negative manner,
influencing cell survival, as has been demonstrated by Morgan
et al (1997). However, its presence would not be expected to
impact on the kinase activity, which would originate solely from
the protein expressed from the wild-type allele. It is formally
possible that alternative start codons in the ATM coding region
may exist downstream of the premature termination codons
carried in the ATM heterozygotes. Translation initiating at such
codons might produce an ATM fragment corresponding to the PI-
3 kinase domain that could retain kinase activity, as has been
shown by Morgan et al (1997). Such an alternative mode of
translation has been found in Nijmegen breakage syndrome
patients carrying the common founder mutation 657del5 allele, a
truncating mutation that causes premature termination at codon
219. In these individuals, an NBS protein lacking the native N-
terminus is produced by internal translation initiation within the
NBS1 mRNA using an open-reading frame generated by the
657del5 frameshift (Maser et al, 2001).
This study, characterising several aspects of the DNA damage
response in 14 AT heterozygote cell lines, highlights their diversity
and the difficulties associated with finding a reliable test for the
detection of ATM carriers in the general population. Based on the
results obtained from the experimental approaches used here,
none of the end points alone would allow the assessment of ATM
heterozygosity with a 100% accuracy. As a group, the cell lines with
such a genetic profile have reduced ATM mRNA and protein levels,
and a lower cell survival following exposure to IR, but on an
individual basis some considerable variation is seen, with some AT
heterozygote lines resembling lines carrying a wild-type ATM gene.
The presence of a missense mutation compared to a truncating
mutation is associated with a higher level of ATM mRNA
expression, but a lower cell survival, after exposure to IR. The
determination of the gene expression profile in AT heterozygotes,
in particular genes implicated in cell survival, where the clearest
differences were observed experimentally between the carriers and
noncarriers of an altered ATM gene, is a promising avenue to be
pursued. Watts et al (2002) have also recently reported that LCLs
from AT heterozygotes have a specific expression phenotype based
on baseline and induced changes in response to IR. One important
practical consideration of any approach to identify ATM carriers is
the need to extend the results to peripheral blood lymphocytes,
which will eliminate the requirement of establishing cell lines and
enable its use in a clinical setting.
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